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Background:  In stable outpatients with diastolic dysfunction (DD), identifying high risk patients remains a challenge. Elevated mid-regional pro-
adrenomedullin (MR-proADM) levels have been associated with poor prognosis in patients with acute heart failure.
Methods:  344 stable outpatients with EF>50% on routine echocardiogram were included. Out of the 344, 176 patients had DD. Patients were 
followed for up to 6 years for all cause mortality. BNP, MR-proADM, and mid-regional biomarkers for atrial natriuretic peptide (MR-proANP), 
vasopressin (copeptin), and pro-endothelin 1 (CT-proET) were measured from serum collected at the time of the echocardiogram. Biomarker cutoffs 
were selected based on ROC curves.
Results:  There were 42 deaths among the 176 patients with DD. The AUCs for MR-proADM, MR-proANP and CT-proET were 0.676 (p=0.001), 0.638 
(p=0.007) and 0.628 (p=0.012), respectively. The AUC for BNP and copeptin were not statistically significant. DD patients with high MR-proADM 
(n=87) had significantly increased mortality compared to DD patients with low MR-proADM (p=0.002). (Figure) In multivariate analysis, when 
modeled as continuous variables, MR-proADM reached statistical significance (p=0.029 HR=48.8), while MR-proANP, CT-proET, and Copeptin did not.
Conclusion: MR-proADM is a strong predictor of mortality in stable outpatients with DD. In patients with DD, MR-proADM is a better predictor of 
mortality than BNP, MR-proANP, copeptin, and CT-proET.
